Scientists fix genetic risk factor for Alzheimer's disease in human brain cells

April 9, 2018, Gladstone Institutes
PET scan of a human brain with Alzheimer's disease. Credit: public domain

Using human brain cells, scientists at the Gladstone Institutes discovered the cause of—and a potential solution for—the primary genetic risk factor for Alzheimer's disease, a gene called apoE4.

Having one copy of the apoE4 gene more than doubles a person's likelihood of developing Alzheimer's , and having two copies of the gene increases the risk by 12-fold, as compared to the most common version of the gene, apoE3.

The apoE4 gene creates a protein of the same name. The apoE4 protein differs from the apoE3 protein at only one point, but that single change is enough to alter its main structure and, thus, its function. Scientists have been unclear about why apoE4 is so much more damaging to brain than other versions of the protein.

In a new study published in Nature Medicine, researchers revealed how apoE4 confers its risk for Alzheimer's disease in human brain cells. What's more, they were able to erase the damage caused by apoE4 by changing it, with a small molecule, into a harmless apoE3-like version.

A Better Model

Most Alzheimer's research and are done in mouse models of the disease. However, a succession of clinical trial failures has spurred scientists to turn to other models.

"Drug development for Alzheimer's disease has been largely a disappointment over the past 10 years," says lead author Yadong Huang, MD, PhD, a senior investigator and director of the Center for Translational Advancement at Gladstone. "Many drugs work beautifully in a mouse model, but so far they've all failed in clinical trials. One concern within the field has been how poorly these mouse models really mimic human disease."

Instead, Huang decided to use to model the disease and test new drugs. Thanks to induced pluripotent stem cell technology, his team was able to examine, for the first time, the effect of apoE4 on human brain cells. To do so, the researchers created neurons from skin cells donated by Alzheimer's patients with two copies of the apoE4 gene, as well as from healthy individuals who had two copies of the apoE3 gene.

The researchers confirmed that, in human neurons, the misshapen apoE4 protein cannot function properly and is broken down into disease-causing fragments in the cells. This process results in a number of problems commonly found in Alzheimer's disease, including the accumulation of the protein tau and of amyloid peptides.

Notably, the presence of apoE4 does not change the production of in mouse neurons. But in human cells, scientists noticed apoE4 has a very clear effect on increasing amyloid beta production, which highlights the species difference in the way apoE4 controls amyloid beta metabolism.

"There's an important species difference in the effect of apoE4 on amyloid beta," says Chengzhong Wang, PhD, the first author on the paper and former research scientist at Gladstone. "Increased amyloid beta production is not seen in mouse neurons and could potentially explain some of the discrepancies between mice and humans regarding drug efficacy. This will be very important information for future drug development."

Fixing a Toxic Protein

Once the scientists confirmed that apoE4 does, indeed, cause damage in human cells related to Alzheimer's disease, a key question remained: how does the presence of apoE4 lead to cell damage? Is the presence of apoE4 resulting in a loss of normal apoE3 function, or does the addition of apoE4 cause the toxic effects?

"It's fundamentally important to address this question because it changes how you treat the problem," explains Huang, who is also a professor of neurology and pathology at UC San Francisco. "If the damage is caused due to the loss of a protein's function, you would want to increase protein levels to supplement those functions. But if the accumulation of a protein leads to a toxic function, you want to lower production of the protein to block its detrimental effect."

To answer this question, the researchers examined brain cells that did not produce either form of the apoE protein, and the neurons looked and functioned just like cells with apoE3. However, if the researchers added apoE4, the cells became riddled with pathologies related to Alzheimer's disease. This discovery indicates that the presence of apoE4—and not the absence of apoE3—promotes the disease.

Finally, the researchers looked for ways to repair the abnormalities caused by apoE4. In earlier work, Huang and his collaborators developed a class of compounds that can change the structure of the harmful apoE4 protein so it resembles the innocuous apoE3 , referred to as apoE4 "structure correctors".

Treating human apoE4 neurons with a structure corrector eliminated the signs of Alzheimer's disease, restored normal function to the cells, and improved cell survival. Huang is now working with his collaborators in academia and the pharmaceutical industry to improve the compounds so they can be tested in human patients in the future.

Explore further: Scientists reveal why people with the ApoE4 gene are more susceptible to Alzheimer's disease

More information: Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector, Nature Medicine (2018) doi:10.1038/s41591-018-0004-z

Related Stories

Scientists reveal why people with the ApoE4 gene are more susceptible to Alzheimer's disease

August 17, 2016
For decades, scientists have known that people with two copies of a gene called apolipoprotein E4 (ApoE4) are much more likely to have Alzheimer's disease at age 65 than the rest of the population. Now, researchers at the ...

Newly ID'd role of major Alzheimer's gene suggests possible therapeutic target

September 20, 2017
Nearly a quarter century ago, a genetic variant known as ApoE4 was identified as a major risk factor for Alzheimer's disease—one that increases a person's chances of developing the neurodegenerative disease by up to 12 ...

An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 in vivo

June 30, 2016
The pathological hallmarks of Alzheimer's disease (AD), viz defective Aβ and tau proteins, have been the center of AD-directed therapeutic studies. Although this approach still remains valid, it has not yet produced clinically ...

Drug's effect on Alzheimer's may depend on severity of disease

July 16, 2014
A cancer drug that has shown promise against Alzheimer's disease in mice and has begun early clinical trials has yielded perplexing results in a novel mouse model of AD that mimics the genetics and pathology of the human ...

Gene linked to Alzheimer's disease impairs memory by disrupting brain's 'playback system'

May 6, 2016
Scientists at the Gladstone Institutes have discovered how the major genetic risk factor for Alzheimer's disease causes memory impairment. A specific type of brain activity important for memory replay is disrupted in mice ...

Recommended for you

Pregnancy history may be tied to Alzheimer's disease

July 18, 2018
A woman's history of pregnancy may affect her risk of Alzheimer's disease decades later, according to a study published in the July 18, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology. ...

Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

July 17, 2018
In a small study of military personnel who had suffered head trauma and had reported memory and mood problems, UCLA researchers found brain changes similar to those seen in retired football players with suspected chronic ...

Yale-developed test for Alzheimer's disease directly measures synaptic loss

July 16, 2018
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer's disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, ...

New study highlights Alzheimer's herpes link, experts say

July 12, 2018
A new commentary by scientists at the Universities of Manchester and Edinburgh on a study by Taiwanese epidemiologists supports the viability of a potential way to reduce the risk of Alzheimer's disease.

Practice imperfect—repeated cognitive testing can obscure early signs of dementia

July 12, 2018
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.

The 'Big Bang' of Alzheimer's: Scientists ID genesis of disease, focus efforts on shape-shifting tau

July 10, 2018
Scientists have discovered a "Big Bang" of Alzheimer's disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.